Trial Profile
A Phase 1 clinical trial of CT P59 (anti-viral monoclonal antibody) in mild COVID-19 patients
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Aug 2020
Price :
$35
*
At a glance
- Drugs Regdanvimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Celltrion
- 26 Aug 2020 According to a Celltrion media release, it has initiated enrolment of patients with mild symptoms of SARS-CoV-2 infection and the clinical trial is set to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of CT-P59.
- 26 Aug 2020 Status changed from planning to recruiting.
- 30 Jul 2020 According to a Celltrion media release, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Clinical Trial Authorisation (CTA) application for this study